IRS Awards Array Firms $16M to Develop Next-Generation Tests
November 16, 2010
IRS Awards Array Firms $16M to Develop Next-Generation Tests
Companies developing array- or biochip-based molecular diagnostics received a shot in the arm earlier this month under the Internal Revenue Service's $1 billion Qualifying Therapeutic Discovery Project program.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - Dx Firms GenMark, Nanosphere, CombiMatrix Attribute Q1 Revenue Growth to Sales Efforts
May 14, 2013 / BioArray News - Array-Based Tests Advance as Dx Firms Engage FDA, Raise Capital, Report Revenue Growth
May 15, 2012 / BioArray News - Diagnostic Revenues Drive up CombiMatrix Q2 Revenues 31 Percent
August 10, 2011 / GenomeWeb Daily News - Nanosphere Will Submit Troponin Assay to FDA This Year, Expand European Launch
May 3, 2011 / BioArray News